The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...
Global pharmaceutical company Eli Lilly's (LLY) preliminary 2024 revenue missed expectations on lower-than-expected sales of ...
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...